Published in Medical Letter on the CDC and FDA, April 14th, 2002
The industry has long funded a significant portion of the FDA's drug review work. But for the first time, this agreement would allow some of that money to go to improved safety monitoring of new drugs - allowing the FDA to eventually double its number of staffers who oversee the risks of newly sold therapies.
Health and Human Services Secretary Tommy Thompson called that part of the deal essential to protecting public health.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.